Table 4 Baseline phenotype of patients developing or not developing acute CV events over the follow up (seven missing patients excluded from the analysis)
New CV events 18 (6.4%) | No new CV events 264 (93.6%) | p value | |
|---|---|---|---|
Age (years) | 66.6 ± 8.0 | 63.0 ± 11.8 | ns |
Sex (n; %) | F 3; 16.6% M 15; 83.2% | F 122; 46.2% M 142; 53.8% | 0.0146 |
BMI (kg/m2) | 28.7 ± 5.0 | 30.5 ± 5.9 | ns |
SBP (mmHg) | 142.7 ± 21.2 | 140.5 ± 19.7 | ns |
DBP (mmHg) | 81.4 ± 10.4 | 83.0 ± 11.0 | ns |
Fasting glucose (mg/dL) | 138 ± 51 | 159 ± 58 | ns |
Hb1Ac (%) | 7.3 ± 1.0 | 7.7 ± 1.8 | ns |
Total cholesterol (mg/dL) | 185 ± 29 | 203 ± 43 | ns |
HDL-cholesterol (mg/dL) | 43 ± 11 | 48 ± 14 | ns |
LDL-cholesterol (mg/dL) | 114 ± 27 | 123 ± 43 | ns |
Triglycerides (mg/dL) | 140 ± 49 | 170 ± 108 | ns |
ALT (IU/L) | 25 ± 9 | 32 ± 23 | ns |
AST (IU/L) | 23 ± 4 | 25 ± 13 | ns |
γGT (IU/L) | 41 ± 25 | 50 ± 60 | ns |
Serum creatinine (mg/dL) | 1.07 ± 0.3 | 0.94 ± 0.42 | ns |
eGFR CKD-EPI (mL/min/1.73 m2) | 71.8 ± 17.3 | 80.0 ± 21.2 | ns |
eGFR < 60 mL/min/1.73 m2 (n; %) | 3; 16.7 | 34; 12.9 | ns |
Uric acid (mg/dL) | 6.6 ± 1.2 | 5.9 ± 1.8 | ns |
Previous CV disease (n; %) | 9; 50.0 | 33; 12.5 | < 0.0001 |
Heart failure (n; %) | 3; 16.7 | 15; 5.7 | ns |
Atrial fibrillation (n; %) | 1; 5.6 | 22; 8.3 | ns |
Any cancer (n; %) | 5; 27.8 | 45; 17.0 | ns |
Diabetic retinopathy (n; %) | 3; 16.7 | 4; 1.5 | < 0.0002 |
No treatment (n; %) | 8; 44.4 | 143; 54.2 | 0.0400 |
Metformin (n; %) | 3; 16.7 | 79; 29.9 | |
Secretagogues (n; %) | 7; 38.9 | 42; 15.9 | |
Anti-hypertensive treatment (n; %) | 13; 72.2 | 160; 60.1 | ns |
Statins (n; %) | 7; 41.1% | 76; 29.0% | ns |